MktsMarkets

Halozyme Therapeutics, Inc.
NASDAQ: HALOKey statistics
HALO News
Stories mentioning HALO from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 376,708 | 451,767 | 354,264 | 325,719 | 264,861 | 298,008 | 290,084 | 231,353 |
| Cost of Goods Sold | 79,238 | 78,770 | 55,242 | 46,359 | 48,403 | 42,055 | 49,426 | 39,607 |
| Gross Profit | 297,470 | 372,997 | 299,022 | 279,360 | 216,458 | 255,953 | 240,658 | 191,746 |
| Operating Expenses | ||||||||
| Research & Development | 25,560 | 17,251 | 17,543 | 14,799 | 20,441 | 18,458 | 21,038 | |
| Sales General & Admin | 57,881 | 77,028 | 46,088 | 41,614 | 42,362 | 42,249 | 41,241 | 35,711 |
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | 184,517 | (92,891) | 217,921 | 202,441 | 141,535 | 175,501 | 163,197 | 117,235 |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 1,318 | 2,430 | 5,333 | 6,891 | 6,818 | 7,253 | 6,474 | 5,032 |
| Pretax Income | 180,327 | (100,849) | 218,958 | 204,938 | 143,828 | 178,214 | 165,147 | 117,743 |
| Tax Provision | 30,278 | 40,742 | 43,733 | 39,778 | 25,733 | 41,202 | 28,136 | 24,498 |
| Net Income (Loss) | 150,049 | (141,591) | 175,225 | 165,160 | 118,095 | 137,012 | 137,011 | 93,245 |
| Earnings Per Share (Basic) | 1.27 | (1.18) | 1.49 | 1.36 | 0.96 | 1.08 | 1.08 | 0.73 |
| Earnings Per Share (Diluted) | 1.22 | (1.14) | 1.43 | 1.33 | 0.93 | 1.06 | 1.05 | 0.72 |
| Weighted Average Shares Outstanding (Basic) | 118,144 | 119,840 | 117,219 | 121,343 | 123,215 | 126,827 | 126,850 | 127,116 |
| Weighted Average Shares Outstanding (Diluted) | 122,875 | 123,904 | 122,331 | 124,158 | 126,644 | 129,424 | 130,134 | 129,222 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About HALO
Halozyme Therapeutics, Inc. (NASDAQ: HALO) is a stock listed on the Nasdaq Stock Market under the ticker symbol HALO. It last traded at $93.04 (Nov 19, 2026, 4:00 PM ET), down 2.9% on the day. That gives Halozyme Therapeutics a market capitalisation of $10.9B and a price-to-earnings ratio of 26.4.
Over the past 52 weeks HALO has traded between $61.23 and $134.00.
Revenue for the quarter ended Mar 31, 2026 was $376.7M; net income $150.0M. Revenue was up 42.2% from $264.9M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $376.7M | $150.0M | 39.8% |
| Dec 31, 2025 | $451.8M | -$141.6M | -31.3% |
| Sep 30, 2025 | $354.3M | $175.2M | 49.5% |
| Jun 30, 2025 | $325.7M | $165.2M | 50.7% |
From Halozyme Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…